Health Canada and Australia Tighten NAION Warnings for GLP-1 Drugs
Event summary
- Health Canada updated Ozempic and Mounjaro product monographs on June 23, 2026 to include enhanced NAION safety information.
- Australia's TGA issued similar updates for GLP-1 medications including Ozempic, Wegovy, Mounjaro, Saxenda, and Trulicity on July 23, 2026.
- Regulators now direct physicians to urgently evaluate sudden vision loss and discontinue treatment if NAION is confirmed.
- Parker Waichman LLP is actively pursuing legal cases for individuals affected by vision loss from GLP-1 medications.
The big picture
Health Canada and Australia's TGA have taken significant steps to strengthen safety information regarding NAION, a rare but potentially permanent cause of vision loss associated with certain GLP-1 medications. These actions represent an important development in regulatory oversight of GLP-1 drugs, which have seen rapid adoption for weight management and type 2 diabetes treatment. The updated guidance includes specific recommendations for physicians, marking a shift from general warnings to detailed clinical instructions.
What we're watching
- Regulatory Headwinds
- Whether other major regulators will follow Health Canada and TGA in issuing detailed NAION guidance for GLP-1 medications.
- Legal Exposure
- The pace at which pending lawsuits against GLP-1 manufacturers may escalate following these regulatory updates.
- Market Impact
- How these safety updates will affect the prescribing patterns and market share of affected GLP-1 medications.
Related topics